Global Hormone Refractory Prostate Cancer (HRPCA) Market 2022 by Company, Regions, Type and Application, Forecast to 2028

  • receipt Report ID : 111897
  • calendar_today Published On: Mar, 2022
  • file_copy Pages: 156
  • list Pharmaceuticals and Healthcare
Buy @ $3500

The Hormone Refractory Prostate Cancer (HRPCA) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest study, due to COVID-19 pandemic, the global Hormone Refractory Prostate Cancer (HRPCA) market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospitals accounting for % of the Hormone Refractory Prostate Cancer (HRPCA) global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Cytotoxic Agents segment is altered to a % CAGR between 2022 and 2028.

Global key companies of Hormone Refractory Prostate Cancer (HRPCA) include Astellas Inc, Sanofi S.A, Dendreon Corporation, Bayer AG, Johnson & Johnson, and , etc. In terms of revenue, the global top four players hold a share over % in 2021.

Market segmentation

Hormone Refractory Prostate Cancer (HRPCA) market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

Cytotoxic Agents

Anti-Androgens

Vaccines

Radio-Pharmaceuticals

Market segment by Application, can be divided into

Hospitals

Ambulatory Surgical Centers

Specialty Clinics

Others

Market segment by players, this report covers

Astellas Inc

Sanofi S.A

Dendreon Corporation, Bayer AG

Johnson & Johnson

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)

South America (Brazil, Argentina, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:

Chapter 1, to describe Hormone Refractory Prostate Cancer (HRPCA) product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top players of Hormone Refractory Prostate Cancer (HRPCA), with revenue, gross margin and global market share of Hormone Refractory Prostate Cancer (HRPCA) from 2019 to 2022.

Chapter 3, the Hormone Refractory Prostate Cancer (HRPCA) competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Hormone Refractory Prostate Cancer (HRPCA) market forecast, by regions, type and application, with revenue, from 2023 to 2028.

Chapter 11 and 12, to describe Hormone Refractory Prostate Cancer (HRPCA) research findings and conclusion, appendix and data source.

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Market Overview

1.1 Product Overview and Scope of Hormone Refractory Prostate Cancer (HRPCA)

1.2 Classification of Hormone Refractory Prostate Cancer (HRPCA) by Type

1.2.1 Overview: Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type: 2017 Versus 2021 Versus 2028

1.2.2 Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Type in 2021

1.2.3 Cytotoxic Agents

1.2.4 Anti-Androgens

1.2.5 Vaccines

1.2.6 Radio-Pharmaceuticals

1.3 Global Hormone Refractory Prostate Cancer (HRPCA) Market by Application

1.3.1 Overview: Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application: 2017 Versus 2021 Versus 2028

1.3.2 Hospitals

1.3.3 Ambulatory Surgical Centers

1.3.4 Specialty Clinics

1.3.5 Others

1.4 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size & Forecast

1.5 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast by Region

1.5.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region: 2017 VS 2021 VS 2028

1.5.2 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region, (2017-2022)

1.5.3 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size and Prospect (2017-2028)

1.5.4 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size and Prospect (2017-2028)

1.5.5 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size and Prospect (2017-2028)

1.5.6 South America Hormone Refractory Prostate Cancer (HRPCA) Market Size and Prospect (2017-2028)

1.5.7 Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size and Prospect (2017-2028)

1.6 Market Drivers, Restraints and Trends

1.6.1 Hormone Refractory Prostate Cancer (HRPCA) Market Drivers

1.6.2 Hormone Refractory Prostate Cancer (HRPCA) Market Restraints

1.6.3 Hormone Refractory Prostate Cancer (HRPCA) Trends Analysis

2 Company Profiles

2.1 Astellas Inc

2.1.1 Astellas Inc Details

2.1.2 Astellas Inc Major Business

2.1.3 Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Product and Solutions

2.1.4 Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.1.5 Astellas Inc Recent Developments and Future Plans

2.2 Sanofi S.A

2.2.1 Sanofi S.A Details

2.2.2 Sanofi S.A Major Business

2.2.3 Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Product and Solutions

2.2.4 Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.2.5 Sanofi S.A Recent Developments and Future Plans

2.3 Dendreon Corporation, Bayer AG

2.3.1 Dendreon Corporation, Bayer AG Details

2.3.2 Dendreon Corporation, Bayer AG Major Business

2.3.3 Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Product and Solutions

2.3.4 Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.3.5 Dendreon Corporation, Bayer AG Recent Developments and Future Plans

2.4 Johnson & Johnson

2.4.1 Johnson & Johnson Details

2.4.2 Johnson & Johnson Major Business

2.4.3 Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Product and Solutions

2.4.4 Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.4.5 Johnson & Johnson Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Hormone Refractory Prostate Cancer (HRPCA) Revenue and Share by Players (2019, 2020, 2021, and 2022)

3.2 Market Concentration Rate

3.2.1 Top 3 Hormone Refractory Prostate Cancer (HRPCA) Players Market Share in 2021

3.2.2 Top 10 Hormone Refractory Prostate Cancer (HRPCA) Players Market Share in 2021

3.2.3 Market Competition Trend

3.3 Hormone Refractory Prostate Cancer (HRPCA) Players Head Office, Products and Services Provided

3.4 Hormone Refractory Prostate Cancer (HRPCA) Mergers & Acquisitions

3.5 Hormone Refractory Prostate Cancer (HRPCA) New Entrants and Expansion Plans

4 Market Size Segment by Type

4.1 Global Hormone Refractory Prostate Cancer (HRPCA) Revenue and Market Share by Type (2017-2022)

4.2 Global Hormone Refractory Prostate Cancer (HRPCA) Market Forecast by Type (2023-2028)

5 Market Size Segment by Application

5.1 Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Application (2017-2022)

5.2 Global Hormone Refractory Prostate Cancer (HRPCA) Market Forecast by Application (2023-2028)

6 North America by Country, by Type, and by Application

6.1 North America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2017-2028)

6.2 North America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2017-2028)

6.3 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country

6.3.1 North America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Country (2017-2028)

6.3.2 United States Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2017-2028)

6.3.3 Canada Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2017-2028)

6.3.4 Mexico Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2017-2028)

7 Europe by Country, by Type, and by Application

7.1 Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2017-2028)

7.2 Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2017-2028)

7.3 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country

7.3.1 Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue by Country (2017-2028)

7.3.2 Germany Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2017-2028)

7.3.3 France Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2017-2028)

7.3.4 United Kingdom Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2017-2028)

7.3.5 Russia Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2017-2028)

7.3.6 Italy Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2017-2028)

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2017-2028)

8.2 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2017-2028)

8.3 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region

8.3.1 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Revenue by Region (2017-2028)

8.3.2 China Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2017-2028)

8.3.3 Japan Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2017-2028)

8.3.4 South Korea Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2017-2028)

8.3.5 India Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2017-2028)

8.3.6 Southeast Asia Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2017-2028)

8.3.7 Australia Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2017-2028)

9 South America by Country, by Type, and by Application

9.1 South America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2017-2028)

9.2 South America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2017-2028)

9.3 South America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country

9.3.1 South America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Country (2017-2028)

9.3.2 Brazil Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2017-2028)

9.3.3 Argentina Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2017-2028)

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2017-2028)

10.2 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2017-2028)

10.3 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country

10.3.1 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue by Country (2017-2028)

10.3.2 Turkey Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2017-2028)

10.3.3 Saudi Arabia Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2017-2028)

10.3.4 UAE Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2017-2028)

11 Research Findings and Conclusion

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type, (USD Million), 2017 VS 2021 VS 2028

Table 2. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application, (USD Million), 2017 VS 2021 VS 2028

Table 3. Global Market Hormone Refractory Prostate Cancer (HRPCA) Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)

Table 4. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million) by Region (2017-2022)

Table 5. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Region (2023-2028)

Table 6. Astellas Inc Corporate Information, Head Office, and Major Competitors

Table 7. Astellas Inc Major Business

Table 8. Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Product and Solutions

Table 9. Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 10. Sanofi S.A Corporate Information, Head Office, and Major Competitors

Table 11. Sanofi S.A Major Business

Table 12. Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Product and Solutions

Table 13. Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 14. Dendreon Corporation, Bayer AG Corporate Information, Head Office, and Major Competitors

Table 15. Dendreon Corporation, Bayer AG Major Business

Table 16. Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Product and Solutions

Table 17. Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 18. Johnson & Johnson Corporate Information, Head Office, and Major Competitors

Table 19. Johnson & Johnson Major Business

Table 20. Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Product and Solutions

Table 21. Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 22. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)

Table 23. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Players (2019, 2020, 2021, and 2022)

Table 24. Breakdown of Hormone Refractory Prostate Cancer (HRPCA) by Company Type (Tier 1, Tier 2 and Tier 3)

Table 25. Hormone Refractory Prostate Cancer (HRPCA) Players Head Office, Products and Services Provided

Table 26. Hormone Refractory Prostate Cancer (HRPCA) Mergers & Acquisitions in the Past Five Years

Table 27. Hormone Refractory Prostate Cancer (HRPCA) New Entrants and Expansion Plans

Table 28. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million) by Type (2017-2022)

Table 29. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Type (2017-2022)

Table 30. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Forecast by Type (2023-2028)

Table 31. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2017-2022)

Table 32. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Forecast by Application (2023-2028)

Table 33. North America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2017-2022) & (USD Million)

Table 34. North America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2023-2028) & (USD Million)

Table 35. North America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2017-2022) & (USD Million)

Table 36. North America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2023-2028) & (USD Million)

Table 37. North America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Country (2017-2022) & (USD Million)

Table 38. North America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Country (2023-2028) & (USD Million)

Table 39. Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2017-2022) & (USD Million)

Table 40. Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2023-2028) & (USD Million)

Table 41. Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2017-2022) & (USD Million)

Table 42. Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2023-2028) & (USD Million)

Table 43. Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue by Country (2017-2022) & (USD Million)

Table 44. Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue by Country (2023-2028) & (USD Million)

Table 45. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2017-2022) & (USD Million)

Table 46. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2023-2028) & (USD Million)

Table 47. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2017-2022) & (USD Million)

Table 48. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2023-2028) & (USD Million)

Table 49. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Revenue by Region (2017-2022) & (USD Million)

Table 50. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Revenue by Region (2023-2028) & (USD Million)

Table 51. South America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2017-2022) & (USD Million)

Table 52. South America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2023-2028) & (USD Million)

Table 53. South America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2017-2022) & (USD Million)

Table 54. South America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2023-2028) & (USD Million)

Table 55. South America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Country (2017-2022) & (USD Million)

Table 56. South America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Country (2023-2028) & (USD Million)

Table 57. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2017-2022) & (USD Million)

Table 58. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2023-2028) & (USD Million)

Table 59. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2017-2022) & (USD Million)

Table 60. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2023-2028) & (USD Million)

Table 61. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue by Country (2017-2022) & (USD Million)

Table 62. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue by Country (2023-2028) & (USD Million)

List of Figures

Figure 1. Hormone Refractory Prostate Cancer (HRPCA) Picture

Figure 2. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Type in 2021

Figure 3. Cytotoxic Agents

Figure 4. Anti-Androgens

Figure 5. Vaccines

Figure 6. Radio-Pharmaceuticals

Figure 7. Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Application in 2021

Figure 8. Hospitals Picture

Figure 9. Ambulatory Surgical Centers Picture

Figure 10. Specialty Clinics Picture

Figure 11. Others Picture

Figure 12. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size, (USD Million): 2017 VS 2021 VS 2028

Figure 13. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue and Forecast (2017-2028) & (USD Million)

Figure 14. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Region (2017-2028)

Figure 15. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Region in 2021

Figure 16. North America Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million) and Growth Rate (2017-2028)

Figure 17. Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million) and Growth Rate (2017-2028)

Figure 18. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million) and Growth Rate (2017-2028)

Figure 19. South America Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million) and Growth Rate (2017-2028)

Figure 20. Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million) and Growth Rate (2017-2028)

Figure 21. Hormone Refractory Prostate Cancer (HRPCA) Market Drivers

Figure 22. Hormone Refractory Prostate Cancer (HRPCA) Market Restraints

Figure 23. Hormone Refractory Prostate Cancer (HRPCA) Market Trends

Figure 24. Astellas Inc Recent Developments and Future Plans

Figure 25. Sanofi S.A Recent Developments and Future Plans

Figure 26. Dendreon Corporation, Bayer AG Recent Developments and Future Plans

Figure 27. Johnson & Johnson Recent Developments and Future Plans

Figure 28. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Players in 2021

Figure 29. Hormone Refractory Prostate Cancer (HRPCA) Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021

Figure 30. Global Top 3 Players Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share in 2021

Figure 31. Global Top 10 Players Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share in 2021

Figure 32. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)

Figure 33. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Type in 2021

Figure 34. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share Forecast by Type (2023-2028)

Figure 35. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Application in 2021

Figure 36. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share Forecast by Application (2023-2028)

Figure 37. North America Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Type (2017-2028)

Figure 38. North America Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Application (2017-2028)

Figure 39. North America Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Country (2017-2028)

Figure 40. United States Hormone Refractory Prostate Cancer (HRPCA) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 41. Canada Hormone Refractory Prostate Cancer (HRPCA) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 42. Mexico Hormone Refractory Prostate Cancer (HRPCA) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 43. Europe Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Type (2017-2028)

Figure 44. Europe Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Application (2017-2028)

Figure 45. Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Country (2017-2028)

Figure 46. Germany Hormone Refractory Prostate Cancer (HRPCA) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 47. France Hormone Refractory Prostate Cancer (HRPCA) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 48. United Kingdom Hormone Refractory Prostate Cancer (HRPCA) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 49. Russia Hormone Refractory Prostate Cancer (HRPCA) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 50. Italy Hormone Refractory Prostate Cancer (HRPCA) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 51. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Type (2017-2028)

Figure 52. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Application (2017-2028)

Figure 53. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Region (2017-2028)

Figure 54. China Hormone Refractory Prostate Cancer (HRPCA) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 55. Japan Hormone Refractory Prostate Cancer (HRPCA) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 56. South Korea Hormone Refractory Prostate Cancer (HRPCA) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 57. India Hormone Refractory Prostate Cancer (HRPCA) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 58. Southeast Asia Hormone Refractory Prostate Cancer (HRPCA) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 59. Australia Hormone Refractory Prostate Cancer (HRPCA) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 60. South America Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Type (2017-2028)

Figure 61. South America Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Application (2017-2028)

Figure 62. South America Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Country (2017-2028)

Figure 63. Brazil Hormone Refractory Prostate Cancer (HRPCA) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 64. Argentina Hormone Refractory Prostate Cancer (HRPCA) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 65. Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Type (2017-2028)

Figure 66. Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Application (2017-2028)

Figure 67. Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Country (2017-2028)

Figure 68. Turkey Hormone Refractory Prostate Cancer (HRPCA) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 69. Saudi Arabia Hormone Refractory Prostate Cancer (HRPCA) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 70. UAE Hormone Refractory Prostate Cancer (HRPCA) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 71. Methodology

Figure 72. Research Process and Data Source

shopping_cart License Type

Buy Now

email Quick Contact

+1

tag_faces Our Clients

help Need Help?

Please contact directly on our US and India numbers

+1-201-465-4211

Please feel free to write an email to us or to use our electronic ticketing system.

sales@marketquest.biz